CRISPR Therapeutics Post Q3 Earnings: Testing Investor Patience, But Still A Buy

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...
Nature

CRISPR vs. cholesterol: can gene editing prevent heart disease?

Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...

Penn, CHOP will test gene therapy for rare diseases with new FDA trial protocol

Penn and CHOP researchers want to develop urea cycle disorder treatments using CRISPR gene-editing therapy. Get unlimited access to Inquirer.com and The Inquirer App, plus 5 articles each month to ...

Dyadic outlines new commercial focus as first bulk protein sales and Asia expansion accelerate growth trajectory

Q3 2025 Management View President & COO Joseph Hazelton highlighted a pivotal shift, stating Dyadic is now operating as a “commercially focused biotechnology company with a growing portfolio of ...